Barriers to a cure for HIV in women

Distinct biological factors exist that affect the natural history of HIV and the host immune response between women and men. These differences must be addressed to permit the optimal design of effective HIV eradication strategies for much of the HIV‐positive population.

• Publication year

  2016

• Venue

  Journal of the International AIDS Society

• Publication date

  2016-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.7448/IAS.19.1.20706PMID 26900031PMCID 4761692
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Systematic Review of the Inclusion (or Exclusion) of Women in HIV Research: From Clinical Studies of Antiretrovirals and Vaccines to Cure Strategies

  2016cited by this paper
• B-108 Specific HIV integration sites are linked to clonal expansion and persistence of infected cells

  2016cited by this paper
• Association between injectable progestin-only contraceptives and HIV acquisition and HIV target cell frequency in the female genital tract in South African women: a prospective cohort study.

  2016cited by this paper
• Estrogen receptors regulate innate immune cells and signaling pathways

  2015cited by this paper
• Sex-based differences in immune function and responses to vaccination.

  2015cited by this paper
• Cervicovaginal microbiota: simple is better.

  2015cited by this paper
• Hydrogen Peroxide–Producing Lactobacilli Are Associated With Lower Levels of Vaginal Interleukin-1&bgr;, Independent of Bacterial Vaginosis

  2015cited by this paper
• Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract.

  2015cited by this paper
• Persistent HIV-1 replication maintains the tissue reservoir during therapy

  2015influential reference
• Sex-Driven Differences in Immunological Responses: Challenges and Opportunities for the Immunotherapies of the Third Millennium

  2015cited by this paper
• Sex, Age, Race and Intervention Type in Clinical Studies of HIV Cure: A Systematic Review

  2015cited by this paper
• Select host restriction factors are associated with HIV persistence during antiretroviral therapy

  2015cited by this paper
• Early Defensive Mechanisms against Human Papillomavirus Infection

  2015cited by this paper
• Bacterial Vaginosis and Subclinical Markers of Genital Tract Inflammation and Mucosal Immunity

  2015cited by this paper
• Progestin-Containing Contraceptives Alter Expression of Host Defense-Related Genes of the Endometrium and Cervix

  2015cited by this paper
• Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy

  2015cited by this paper
• Hormonal modulation of the immune system - A spotlight on the role of progestogens.

  2015influential reference
• Immune Cells in the Female Reproductive Tract

  2015cited by this paper
• Human adipose tissue as a reservoir for memory CD4+ T cells and HIV

  2015cited by this paper
• CD4+ and CD8+ T Cell Activation Are Associated with HIV DNA in Resting CD4+ T Cells

  2014cited by this paper
• Estrogen’s effects in chronic autoimmune/inflammatory diseases and progression to cancer

  2014cited by this paper
• Hormonal milieu at time of B cell activation controls duration of autoantibody response.

  2014cited by this paper
• Factors Associated with D-Dimer Levels in HIV-Infected Individuals

  2014cited by this paper
• 17β-Estradiol Protects Primary Macrophages Against HIV Infection Through Induction of Interferon-Alpha

  2014cited by this paper
• Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202.

  2014cited by this paper
• Specific HIV integration sites are linked to clonal expansion and persistence of infected cells

  2014influential reference
• X-Chromosome Complement and Estrogen Receptor Signaling Independently Contribute to the Enhanced TLR7-Mediated IFN-α Production of Plasmacytoid Dendritic Cells from Women

  2014cited by this paper
• Influence of Common Mucosal Co‐Factors on HIV Infection in the Female Genital Tract

  2014cited by this paper
• Steroids and the blood-brain barrier: therapeutic implications.

  2014influential reference
• Policy: NIH to balance sex in cell and animal studies

  2014cited by this paper
• How Might We Cure HIV?

  2014cited by this paper
• Sex-based differences in HIV type 1 pathogenesis.

  2014influential reference
• Phenotype and Functionality of CD4+ and CD8+ T Cells in the Upper Reproductive Tract of Healthy Premenopausal Women

  2014cited by this paper
• Characterization of the Immune Cell Repertoire in the Normal Fallopian Tube

  2014cited by this paper
• The sexually dimorphic role of adipose and adipocyte estrogen receptors in modulating adipose tissue expansion, inflammation, and fibrosis.

  2013cited by this paper
• Behavioral, Biological, and Demographic Risk and Protective Factors for New HIV Infections Among Youth in Rakai, Uganda

  2013cited by this paper
• Innate and adaptive anti-HIV immune responses in the female reproductive tract.

  2013cited by this paper
• Association of genital human papillomavirus infection with HIV acquisition: a systematic review and meta-analysis

  2013cited by this paper
• Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure.

  2013cited by this paper
• Age-Associated Changes in Monocyte and Innate Immune Activation Markers Occur More Rapidly in HIV Infected Women

  2013cited by this paper
• Phytoestrogens mediated anti-inflammatory effect through suppression of IRF-1 and pSTAT1 expressions in lipopolysaccharide-activated microglia.

  2013cited by this paper
• Participation of Women and Sex Analyses in Late-Phase Clinical Trials of New Molecular Entity Drugs and Biologics Approved by the FDA in 2007–2009

  2013cited by this paper
• Human Papillomavirus Seropositivity and Subsequent Risk of HIV Acquisition in Rural South African Women

  2013cited by this paper
• Immune activation and HIV persistence: considerations for novel therapeutic interventions

  2013cited by this paper
• Inclusion of minorities and women in cancer clinical trials, a decade later: Have we improved?

  2013cited by this paper
• Higher expression of several interferon-stimulated genes in HIV-1-infected females after adjusting for the level of viral replication.

  2013cited by this paper
• Single and Multiple Dose Pharmacokinetics of Dolutegravir in the Genital Tract of HIV-Negative Women

  2013cited by this paper
• Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women.

  2013cited by this paper
• 17β-Estradiol inhibits HIV-1 by inducing a complex formation between β-catenin and estrogen receptor α on the HIV promoter to suppress HIV transcription.

  2013cited by this paper
• Nuclear Receptor, Coregulator Signaling, and Chromatin Remodeling Pathways Suggest Involvement of the Epigenome in the Steroid Hormone Response of Endometrium and Abnormalities in Endometriosis

  2012cited by this paper
• The TLR-mediated response of plasmacytoid dendritic cells is positively regulated by estradiol in vivo through cell-intrinsic estrogen receptor α signaling.

  2012cited by this paper
• Effect of gender and race on the week 48 findings in treatment‐naïve, HIV‐1‐infected patients enrolled in the randomized, phase III trials ECHO and THRIVE

  2012cited by this paper
• Progesterone and autoimmune disease.

  2012cited by this paper
• Dialogues on Diversifying Clinical Trials: Successful Strategies for Engaging Women and Minorities in Clinical Trials

  2012cited by this paper
• Low-level viraemia on HAART: significance and management

  2012cited by this paper
• The evolving epidemiology of HIV/AIDS

  2012cited by this paper
• Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis.

  2012cited by this paper
• Pharmacokinetics of Antiretroviral Drugs in Anatomical Sanctuary Sites: The Male and Female Genital Tract

  2011cited by this paper
• Effect of menstrual cycle variation in female sex hormones on cellular immunity and regulation.

  2011cited by this paper
• Innate and adaptive immunity at mucosal surfaces of the female reproductive tract: stratification and integration of immune protection against the transmission of sexually transmitted infections.

  2011cited by this paper
• Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 Transmission

  2011cited by this paper
• Outcomes in the First Year after Initiation of First-Line Haart among Heterosexual Men and Women in the Uk Chic Study

  2011cited by this paper
• Estradiol‐dependent perforin expression by human regulatory T‐cells

  2011cited by this paper
• Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers.

  2011cited by this paper
• HIV persistence in the gut mucosa of HIV-infected subjects undergoing antiretroviral therapy correlates with immune activation and increased levels of LPS.

  2011cited by this paper
• Raltegravir Concentrations in the Genital Tract of HIV-1-Infected Women Treated with a Raltegravir-Containing Regimen (DIVA 01 Study)

  2011cited by this paper
• Early HIV‐1 Target Cells in Human Vaginal and Ectocervical Mucosa

  2011cited by this paper
• Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection.

  2011cited by this paper
• Sex bias in neuroscience and biomedical research.

  2011cited by this paper
• Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.

  2010cited by this paper
• Sex Differences in Nevirapine Rash

  2010cited by this paper
• Sex-Based Outcomes of Darunavir–Ritonavir Therapy A Single-Group Trial

  2010cited by this paper
• Sex-Based Outcomes of Darunavir–Ritonavir Therapy

  2010cited by this paper
• Vaginal microbiome of reproductive-age women

  2010cited by this paper
• Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy.

  2010cited by this paper
• PD-1, gender, and autoimmunity.

  2010cited by this paper
• Comparison of Self-Collected and Physician-Collected Vaginal Swabs for Microbiome Analysis

  2010cited by this paper
• HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

  2010cited by this paper
• Type-Specific Cervico-Vaginal Human Papillomavirus Infection Increases Risk of HIV Acquisition Independent of Other Sexually Transmitted Infections

  2010cited by this paper
• The Xs and Y of immune responses to viral vaccines.

  2010cited by this paper
• Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load

  2010cited by this paper
• Of Mice and Women: The Bias in Animal Models

  2010cited by this paper
• Darunavir, Ritonavir, and Etravirine Pharmacokinetics in the Cervicovaginal Fluid and Blood Plasma of HIV-Infected Women

  2010cited by this paper
• Sex bias in trials and treatment must end

  2010cited by this paper
• The X chromosome in immune functions: when a chromosome makes the difference

  2010cited by this paper
• Sex differences in the Toll-like receptor–mediated response of plasmacytoid dendritic cells to HIV-1

  2009cited by this paper
• Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy

  2009cited by this paper
• Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV

  2009cited by this paper
• Estrogen Receptor Alpha Inhibits the Estrogen-Mediated Suppression of HIV Transcription in Astrocytes: Implications for Estrogen Neuroprotection in HIV Dementia

  2009cited by this paper
• Inflammation and Race and Gender Differences in Computerized Tomography‐measured Adipose Depots

  2009cited by this paper
• Sex Differences in Pharmacokinetics and Pharmacodynamics

  2009cited by this paper
• Stronger inflammatory/cytotoxic T cell response in women identified by microarray analysis

  2008cited by this paper
• Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy.

  2008cited by this paper
• Enrollment of women in National Heart, Lung, and Blood Institute-funded cardiovascular randomized controlled trials fails to meet current federal mandates for inclusion.

  2008cited by this paper
• Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

  2008cited by this paper
• Estradiol and Progesterone Regulate HIV Type 1 Replication in Peripheral Blood Cells

  2008cited by this paper
• The X-files in immunity: sex-based differences predispose immune responses

  2008influential reference
• Induction of regulatory T cells by physiological level estrogen

  2008cited by this paper
• Gender differences in the treatment of HIV infection.

  2008cited by this paper
• Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy.

  2008cited by this paper

• ‘It is scary to pause treatment’: perspectives on HIV cure-related research and analytical treatment interruptions from women diagnosed during acute HIV in Durban, South Africa

  2025cites this paper
• The CanCURE Survey: Gender-Based Differences in HIV Cure Research Priorities

  2025influential citation
• Estrogen Modulation of B Cell Immunity: Implications for HIV Control and Therapeutic Strategies

  2025cites this paper
• Resolving Challenges in HIV Cure–Related Research: Protocol for a Modified Delphi Consensus-Building Process

  2025cites this paper
• Gender equality in leadership of HIV care cascade clinical trials: A methodological study

  2025cites this paper
• Willingness to participate in clinical trials and expectations towards antiretroviral therapy among heavily treatment‐experienced people living with HIV: A feasibility survey

  2025cites this paper
• “They Have to Make an Effort Too”: What Decliners Can Teach Us About HIV Cure/Remission-Related Clinical Trials? Results from a French Qualitative Study

  2024cites this paper
• Viral and Immune Risk Factors of HIV Rebound after Interruption of Antiretroviral Therapy.

  2024cites this paper
• Missing voices: building women living with HIV’s meaningful engagement in HIV clinical and cure research

  2024cites this paper
• Sex Differences in HIV Infection.

  2023cites this paper
• Increasing the meaningful involvement of women in HIV cure-related research: a qualitative interview study in the United States

  2023influential citation
• Cardiovascular Implications of Immune Disorders in Women

  2022cites this paper
• Lessons for Understanding Central Nervous System HIV Reservoirs from the Last Gift Program

  2022cites this paper
• A Community Call to Action to Prioritize Inclusion and Enrollment of Women in HIV Cure-related Research

  2022cites this paper
• Facilitators and barriers of women's participation in HIV clinical research in Switzerland: A qualitative study

  2022cites this paper
• HIV Reservoirs: Modeling, Quantification, and Approaches to a Cure.

  2022cites this paper
• Impact of dedicated women’s outreach workers (WOWs) on recruitment of women in ACTG clinical studies

  2021cites this paper
• HIV and women in the USA: what we know and where to go from here.

  2021cites this paper
• Considerations for Increasing Racial, Ethnic, Gender, and Sexual Diversity in HIV Cure-Related Research with Analytical Treatment Interruptions: A Qualitative Inquiry

  2021cites this paper
• Tissue‐specific differences in HIV DNA levels and mechanisms that govern HIV transcription in blood, gut, genital tract and liver in ART‐treated women

  2021cites this paper
• Sex differences in HIV Persistence and Reservoir Size during Aging.

  2021cites this paper
• “I would really want to know that they had my back”: Transgender women’s perceptions of HIV cure-related research in the United States

  2020cites this paper
• A landscape analysis of HIV cure-related clinical research in 2019

  2020cites this paper
• Participant Perspectives in an HIV Cure-Related Trial Conducted Exclusively in Women in the United States: Results from AIDS Clinical Trials Group 5366

  2020influential citation
• Differences in HIV cure clinical trial preferences of French people living with HIV and physicians in the ANRS‐APSEC study: a discrete choice experiment

  2020cites this paper
• Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting

  2019cites this paper
• Gender differences in innate responses and gene expression profiles in memory CD4 T cells are apparent very early during acute simian immunodeficiency virus infection

  2019cites this paper
• Screening and Enrollment by Sex in HIV Clinical Trials in the United States.

  2019cites this paper
• Revisiting the ‘sterilising cure’ terminology: a call for more patient-centred perspectives on HIV cure-related research

  2019cites this paper
• Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.

  2019cites this paper
• A landscape analysis of HIV cure-related clinical trials and observational studies in 2018

  2019cites this paper
• Sex-Based Differences in Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation

  2018cites this paper
• Sex Differences in the Kinetics of Immune Reconstitution under Antiretroviral Therapy

  2018cites this paper
• Pharmacology of Antiretrovirals in the Female Genital Tract for HIV Prevention

  2018cites this paper
• Analysis of Complement-Mediated Lysis of Simian Immunodeficiency Virus (SIV) and SIV-Infected Cells Reveals Sex Differences in Vaccine-Induced Immune Responses in Rhesus Macaques

  2018cites this paper
• Research on HIV cure: Mapping the ethics landscape

  2017cites this paper
• Barriers to HIV remission research in low- and middle-income countries

  2017cites this paper
• International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

  2016cites this paper
• Impressions of the 21st International AIDS Conference in Durban, South Africa.

  2016cites this paper